Your search returned 2 results.

Results
	1.	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors: Swain, Sandra M PMID: 24869931 Year: 2014 Citation: Oncologist. 19(7):693-701, 2014 Jul. Institution: Washington Cancer Institute Form of publication: Journal Article All authors: Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2014-0033 Add to cart (remove)
	2.	Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors: Swain, Sandra M PMID: 27693116 Year: 2017 Citation: Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N DOI: https://dx.doi.org/10.1016/j.clbc.2016.07.008 Add to cart (remove)

Refine your search